Celecoxib 化学構造
分子量: 381.37

高品質保証

カスタマーフィードバック(2)

Quality Control & MSDS

製品説明

  • Compare COX Inhibitors
    COX製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 セレコキシブは、40nMのIC50による選択的なCOX-2阻害剤です。
ターゲット COX-2
IC50 40 nM [1]
In vitro試験 Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A549 NGjkdJJHfW6ldHnvckBCe3OjeR?= MnzyNE4yNTNyIN88US=> NETYWIc1QCCq MULpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> MlO3NlY2OTNzN{K=
H460 NUfoZlVUTnWwY4Tpc44hSXO|YYm= M3LyVlAvOS1|MDFOwG0> MYi0PEBp NVHER5k4cW6mdXPld{BKS0GPLUGg[ZhxemW|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx? MXyyOlUyOzF5Mh?=
HKESC-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PhXFIxyqEQvF2= NX;L[oVFPDkEoHlCpC=> MkPZd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh MViyOlQ4PDZ7Mx?=
CaES-17 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\FNlDDqM7:TR?= MnnNOFjDqGkEoB?= M1vkN5Nq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? M1ix[FI3PDd2Nkmz
HKESC-2 M4rMVmFxd3C2b4Ppd{BCe3OjeR?= NHzEVZkzOMLizszN MlrxOFjDqGkEoB?= M4LROpJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> MVKyOlQ4PDZ7Mx?=
CaES-17 M{\zbGFxd3C2b4Ppd{BCe3OjeR?= NUPoOnJ4OjEEoN88US=> MoC5OFjDqGkEoB?= NWP1WHpnemWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>? NFzvOWYzPjR5NE[5Ny=>
A549 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXy1MVE3OCEQvF2= NFvjOFY1QMLiaNMg M3naNmROW09? NWiyNocxUUN3ME2xOlMvPCEQvF2= MYeyOlQ3PDZ2Mx?=
HCC827 NIrWOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7sdFFIPS1zNkCg{txO NILFdVk1QMLiaNMg MWHEUXNQ MVjJR|UxRTZ7LkKg{txO MnzvNlY1PjR4NEO=
A549 M1S1NGFxd3C2b4Ppd{BCe3OjeR?= NW\jUJFVQDBiwsXN MXy0POKhcMLi MnroSG1UVw>? NYjRZZY{cW6mdXPld{BieG:ydH;zbZM> MVSyOlQ3PDZ2Mx?=
HCC827 MY\BdI9xfG:|aYOgRZN{[Xl? MUK4NEDDvU1? MnjNOFjDqGkEoB?= NESxRVdFVVOR MmL2bY5lfWOnczDhdI9xfG:|aYO= NVz1cYk1OjZ2NkS2OFM>
SGC-7901/DDP NWTO[5VbTnWwY4Tpc44hSXO|YYm= Mo\xNVDDqML3TR?= MnLZNlQhcA>? M4rLV4lvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44> MoP1NlY1ODd4NUO=
SGC-7901  NYLyUHFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTBSYFwOjUEoHlCpC=> NELhZ4tKSzVyPUGxOU4xQCEQvF2= M4S2NVI3PDB5NkWz
SGC-7901/DDP M12yWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f2WVI1yqCqwrC= NIHvfnVKSzVyPUO1MlQ2KM7:TR?= MXmyOlQxPzZ3Mx?=
SGC-7901/DDP MmTGRZBweHSxc3nzJGF{e2G7 NH7vVHQyOMLiwsXN MkT0NlQhcA>? NVTjb3JvcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDD3bZRpKGOrc4DsZZRqdg>? NFK5[XAzPjRyN{[1Ny=>
SGC-7901/DDP NV\hcFdTTnWwY4Tpc44hSXO|YYm= NEHpN5QyOMLiwsXN NUXIOVVMOjRiaB?= M3\NfolvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJHAu\2y7Y3;wdo91\WmwIITodo92\2hiYnzvZ4tqdmdiRWCyMEBidmRiaX7hZ5RqfmG2aX7nJHBMSSCjbnSgR3JGSsLi MV[yOlQxPzZ3Mx?=
SGC-7901/DDP MnLxSpVv[3Srb36gRZN{[Xl? M3vyN|ExyqEEtV2= NXnZXYZ{OjRiaB?= M4Wwc4NifXOnczDhJI1iemunZDDk[YNz\WG|ZTDpckB1cGVibHX2[Ywhd2ZiQnPsMVIheHKxdHXpci=> NUixfIhjOjZ2MEe2OVM>
H357 M4PCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3nVII4NjVxMUCg{txO M3O5eFQ5KGh? NHzPfmhFVVOR MVPpcohq[mm2czDj[YxtKGe{b4f0bOKh[2:vYnnu[YQhf2m2aDDTZYJ2fG:lbHH4 NEfBTJAzPjByOUi3OC=>
TAF MnP3SpVv[3Srb36gRZN{[Xl? MVqxNOKhyrWP MlexO{Bl NIS2SG9i\m[nY4TzJHRCTnNiYXTo[ZNqfmVicILvdIVzfGmncx?= NHnEdHczPTl6N{GyOy=>
TAF NVHhdYoyTnWwY4Tpc44hSXO|YYm= MlPwNVDDqML3TR?= MXGzNE0yOjBibXnu NYHyVoJ1eG:xcnz5JIFn\mWldIOg[GFsfCCyaH;zdIhwenmuYYTpc44h[2:wc3XxeYVvfCC2bzDFS2Yhe2mpbnHsbY5o NF;XdHYzPTl6N{GyOy=>
TAF NHHTfHVHfW6ldHnvckBCe3OjeR?= MlHBNVDDqML3TR?= MXW0PEBp M1O5d4lv[3KnYYPld{BGT0[UIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MXKyOVk5PzF{Nx?=
PANC-1 NEDpSmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljiNlAwPjBxMUCwJO69VQ>? NFfLZm0zPC92OD:3NkBp MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2fBd|I2QTd|ME[y
PANC-1 NIPQU3NHfW6ldHnvckBCe3OjeR?= MonMNlAwPjBxMUCwJO69VQ>? NWK1eoJEOjRiaB?= NI\FVYxifHSnboXheJMh[2WubDDpcpZie2mxbjDhcoQhdWmpcnH0bY9vKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M{flUVI2QTd|ME[y
HeLa  MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fJW|IxyqEQvF5CpC=> M2mwNFI1yqCq MYrlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? NEPtO5YzPTd5MESyNy=>
SACC-83 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSyNOKh|ryPwrC= NYPYOHZ4OjUEoHi= MWDlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? M{XrXlI2PzdyNEKz
HeLa  NHS1XIRCeG:ydH;zbZMhSXO|YYm= NIXLNnczOMLizszNxsA> M2e5PVI1yqCq NF7CSIhmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ MYqyOVc4ODR{Mx?=
SACC-83 Mmr6RZBweHSxc3nzJGF{e2G7 NH7jTHgzOMLizszNxsA> MV6yOOKhcA>? NH;ucFRmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ MVWyOVc4ODR{Mx?=
HeLa  NGHYOGxHfW6ldHnvckBCe3OjeR?= NHzkNFkzOC92MD:4NEDPxE1? MoW2NlTDqGh? MXX1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> NX;SNZRUOjV5N{C0NlM>
SACC-83 NF;iVWRHfW6ldHnvckBCe3OjeR?= NXrGNVJHOjBxNECvPFAh|ryP Mk\sNlTDqGh? NVvDNJBNfXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? NUD6PVlnOjV5N{C0NlM>
HLCZ01 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOw5qCUPjEEoNM1US=> NET2UYs1QCCq NVW2blhMTE2VTx?= M1zXbYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz Ml63NlU4OjR6OUm=
HLCZ01 M{DMNWZ2dmO2aX;uJGF{e2G7 Mn;ROFDDqM7:TR?= NUjNVnpkOjRiaB?= MVLEUXNQ NY\nT|ZWcW6lcnXhd4V{KGGlY4XteYxifGmxbjDv[kBIOC:JMT3wbIF{\SClZXzsd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? MorwNlU4OjR6OUm=
HLCZ01 NXTyd3V5SXCxcITvd4l{KEG|c3H5 MXG0NOKh|ryP NUjDboV5OjRiaB?= MWHEUXNQ MWrlcohidmOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCLRl6t{tE> NWT1eGZrOjV5MkS4PVk>
HLCZ01 M{C1WGZ2dmO2aX;uJGF{e2G7 NFTCT3E1OMLizszN M33pdVI1KGh? NIXRd5hFVVOR M4WzOolv[3KnYYPld{BVWkGLTDDlfJBz\XO|aX;uJINwdWKrbnXkJJdqfGhiSX70[ZJn\XKxbj5OtS=> MX[yOVczPDh7OR?=
MGC803 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr6RnBtOC14MDFOwG0> NWDVPFB4PzJiaB?= NYDaZ3ZZUUN3ME20O{4zPeLCidMx5qCKPi52MzFOwG0> NXP3e|ZJOjV5MEGzO|g>
SGC7901 NXTm[nAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6wMVYxKM7:TR?= NVvqXWI3PzJiaB?= M3HVcmlEPTB;NEOuOVPjiIoEsfMAjVUvOTJizszN MnvJNlU4ODF|N{i=
MGC803 NETwd41HfW6ldHnvckBCe3OjeR?= NITOV4M1OMLizszN M4rGPFgwOTZxMkSgbC=> NVvhcWRyfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v NWG0e45NOjV5MEGzO|g>
SGC7901 M3zSZ2Z2dmO2aX;uJGF{e2G7 M4nRdlQxyqEQvF2= NYX1U3RZQC9zNj:yOEBp M4HGfJVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> NUPYSoJSOjV5MEGzO|g>
MCF-7  M2TscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXmZpkyNzFyIN88US=> MXi3NkBp MXnEUXNQ M3GzV4VvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w M2jsW|I2PjZ5NUGw
MDA-MB-231  M{PDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS0bHI4OS9zMDFOwG0> MlXQO|IhcA>? NUP6NJQ6TE2VTx?= MX7lcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>? NVW0RWtJOjV4Nke1NVA>
MDA-MB-231 MXjGeY5kfGmxbjDBd5NigQ>? NYDDcIoxOC12MDFCuW0> MYO0MVI1KGh? M2D4Xolv[3KnYYPld{BEV1hvMjDwdo91\WmwIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NXO0TlduOjV3OEezNlk>
MCF-7 MojWSpVv[3Srb36gRZN{[Xl? NXr4bZZ1OC12MDFCuW0> MoHpOE0zPCCq Mn25[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? Mly3NlU2QDd|Mkm=
MCF7-MX  MmCwSpVv[3Srb36gRZN{[Xl? NX7kUW9oOC12MDFCuW0> M2nQflQuOjRiaB?= MV\lcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW|c3nvcuKh NGLUNokzPTV6N{OyPS=>
MDA-MB-231 MVvGeY5kfGmxbjDBd5NigQ>? NX7X[4FTOC12MDFCuW0> MWK0MVI1KGh? M4DLVZN1cW23bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhSUKFR{KgeZAhfG9iND6yO{B1cW2nczD0c{Bkd262cn;sJIxmfmWuIHL5JFEzKGkEoB?= MmrNNlU2QDd|Mkm=
A2780 MWTGeY5kfGmxbjDBd5NigQ>? NV3QUHlIPS9zMD:xOUDPxE1? NYPGZYJTPDhiaB?= M2S3dYRm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGWxPI8zPTR{NEi5PC=>
SKOV3  MlHESpVv[3Srb36gRZN{[Xl? MlvmOU8yOC9zNTFOwG0> M1XvOlQ5KGh? M1XNT4Rm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NUK3O2FZOjV2MkS4PVg>
A2780 MkPLSpVv[3Srb36gRZN{[Xl? NUfIU|lGPS9zMD:xOUDPxE1? MUW0PEBp MkP3[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>? NVvXRo1[OjV2MkS4PVg>
SKOV3  MnHVSpVv[3Srb36gRZN{[Xl? Mn3FOU8yOC9zNTFOwG0> MoHYOFghcA>? NHXGcopmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw MUWyOVQzPDh7OB?=
A2780 NH;KcFhHfW6ldHnvckBCe3OjeR?= MonDOU8yOC9zNTFOwG0> NWL5WmZWPDhiaB?= NGT4Znhl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6= NHPjNVczPTR{NEi5PC=>
SKOV3  NXXWdYFbTnWwY4Tpc44hSXO|YYm= NVP4RnE1PS9zMD:xOUDPxE1? Mkn2OFghcA>? MWHk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? M4LGdlI2PDJ2OEm4
A2780 NWr2fYhTTnWwY4Tpc44hSXO|YYm= NH3HXoc2NzFyL{G1JO69VQ>? MkfNNUBp MnjmbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4mwWVI2PDJ2OEm4
SKOV3  MoT2SpVv[3Srb36gRZN{[Xl? NIDQfYk2NzFyL{G1JO69VQ>? MXyxJIg> NITqR4ZqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MV2yOVQzPDh7OB?=
HCT-15 NHrDU|hHfW6ldHnvckBCe3OjeR?= MmCxNVAuPTBizszN M4jaNlYuOzZiaB?= MlzFbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= MoLENlUzOThyMki=
HT-29  NIPwPJFHfW6ldHnvckBCe3OjeR?= NVLSPGVxOTBvNUCg{txO MnjoOk0{PiCq Ml76bY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= MnrkNlUzOThyMki=
HSC3  M4fXW2NmdGxiVnnhZoltcXS7IFHzd4F6 M2\BTlDjiJN2MDFOwG0> MX[0PEBp NFLVWpFKSzVyPUK1MlXDuTFwN{iwJO69VQ>? MYmyOVE6QDd6OR?=
HSC3  NWXDbnF3SXCxcITvd4l{KEG|c3H5 NIDndlMzPSEQvF2= NVSxO2l6PDhiaB?= MUnpcoR2[2W|IHHwc5B1d3Orcx?= MY[yOVE6QDd6OR?=
HSC3  NVzHWYdRTnWwY4Tpc44hSXO|YYm= M372TlI2KM7:TR?= M{K3V|Q5KGh? NGfNXW9mgGirYnn0d{B{cWewaX\pZ4FvfGy7IILl[JVk\WRibXnndoF1cW:wIHPvcYJqdmWmIIfpeIghS0WW Mnu5NlUyQTh5OEm=
HSC3  MUPGeY5kfGmxbjDBd5NigQ>? NULHSmR3OjVizszN NY\nS|l4PDhiaB?= MXzpcohq[mm2czDIV2M{KGOnbHygbY53[XOrb36gZ49u[mmwZXSge4l1cCCFRWS= NFrnc2gzPTF7OEe4PS=>
HSC3  NFezc3FHfW6ldHnvckBCe3OjeR?= NWjrZmk4OjVizszN NVnVS|RLPzJiaB?= MXfk[YNz\WG|ZYOgUW1RNTJiYX7kJG1OWC17IIDyc5RmcW6|wrC= M3XEZVI2OTl6N{i5
201T  M3rac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HSZlczKGh? NYDNT3l7TE2VTx?= M1\XcWlEPTB;NEiuOkDDvU1? NGS3VYozPTB3N{m0NS=>
273T M{\oUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXzUYo4OiCq MXfEUXNQ NUXuXHo3UUN3ME24NE42KML3TR?= MlrxNlUxPTd7NEG=
Hep-2 NH;KRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXflS|JtOzBxNUCvNVAxKM7:TR?= M{LKOFEzNzJ2L{O2M|Q5KGh? MoLxSG1UVw>? Mm\hbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHvaWZIzPDl7OEW2OC=>
Hep-2 MoLURZBweHSxc3nzJGF{e2G7 NVvTRVFRPTBizszN MoXYNE01QCCq NIDrVW1FVVOR NX\HbYd{cW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NHLMVXAzPDl7OEW2OC=>
Hep-2 MmXPSpVv[3Srb36gRZN{[Xl? NF\IW5Q2OCEQvF2= MXuwMVQ5KGh? NFfVeGtFVVOR MkThdoVlfWOnczD0bIUhfGWub33ldoF{\SCjY4Tpeol1gSCpcnHkeYFtdHl? MlLQNlQ6QTh3NkS=
Hep-2 Ml2wSpVv[3Srb36gRZN{[Xl? MnmwOVAh|ryP M1rLeFAuPDhiaB?= MmC5SG1UVw>? NFvQUVZl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>? M1vCcFI1QTl6NU[0
SGC-7901 NVrPfYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjMUlIxOTBxNUCvNVAxKM7:TR?= NXjtWWU6OjRxNEivO|IhcA>? NYTuW|NETE2VTx?= MmHSbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MVGyOFk6Ojl3OB?=
MKN-45 NF3EOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPDWWFXOTBxNUCvNVAxKM7:TR?= NE\nNYUzPC92OD:3NkBp M3LpR2ROW09? NUnxb5ZZcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MljzNlQ6QTJ7NUi=
SGC-7901 MXLGeY5kfGmxbjDBd5NigQ>? MVyxNE82OC9zMECg{txO M4P3RlQ5KGh? M1;abmROW09? NWDCdnM{\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M4[0bVI1QTl{OUW4
MKN-45 NFj5VZBHfW6ldHnvckBCe3OjeR?= MWWxNE82OC9zMECg{txO NGjFeZY1QCCq NFjy[3VFVVOR MorT[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MVuyOFk6Ojl3OB?=
C666-1 MmHUR5l1d3SxeHnjbZR6KEG|c3H5 NGT3dVQzOC16MDFOwG0> MX6yOEBp Ml\N[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> NXPi[2MzOjR6NUS4N|g>
CNE-1 NVfxPYxKS3m2b4TvfIlkcXS7IFHzd4F6 NX[5c|IzOjBvOECg{txO M3GxPFI1KGh? NV7qTYNM\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? M1HmV|I1QDV2OEO4
CNE-2 NV\OZ|c5S3m2b4TvfIlkcXS7IFHzd4F6 MY[yNE05OCEQvF2= MmfPNlQhcA>? NXnRfoFK\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? NUnwV3JQOjR6NUS4N|g>
C666-1 MUHDfZRwfG:6aXPpeJkhSXO|YYm= NWDIbWZEPjBizszN NYnoUZhyPyCm M{i1R4VvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy MY[yOFg2PDh|OB?=
CNE-1 M4H4PGN6fG:2b4jpZ4l1gSCDc4PhfS=> MUO2NEDPxE1? M1;keFch\A>? MYnlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= M3fHOVI1QDV2OEO4
SNU-1041 MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXmeYsxNTRyIN88US=> MWO0PEBp NGXSWYRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NWLLNpk2OjR4OUK3NFM>
SNU-1041 M3TjeWZ2dmO2aX;uJGF{e2G7 MnzVNlAwOzBizszN NWTNd3U2PCCq NHnSN5NqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>? MlLUNlQ3QTJ5MEO=
SNU-1041 NIi5dmFHfW6ldHnvckBCe3OjeR?= MXywMVQxKM7:TR?= NYP3SpBxPCCq MkT2eZAuemWpdXzheIV{KEOKT2FCpIFnfGW{IITy[YF1dWWwdDD3bZRpKGirZ3igZ49v[2WwdILheIlwdnN? MYKyOFY6OjdyMx?=
SGC-7901 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXNeHc2OC1zMkWg{txO NWDk[HY4OjRxNEivO|IhcA>? NGHWToJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MVSyOFY4PjN7NB?=
SGC-7901 M2POTGFxd3C2b4Ppd{BCe3OjeR?= NUm4RogzOTByIN88US=> NVjvbHlWPzJiaB?= MnLNbY5lfWOnczDhdI9xfG:|aYO= M{exWlI1Pjd4M{m0
SGC-7901 MlvrSpVv[3Srb36gRZN{[Xl? MlOxO|UwOTByL{GyOUDPxE1? MUeyOE81QC95MjDo NYnXNlh{cW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI> NVXvUms3OjR4N{[zPVQ>
LMeC  MojTSpVv[3Srb36gRZN{[Xl? NGrnSnQzOC93MDFOwG0> NED5TpI1QCCq NFfZ[IVl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhS0:[LUKgdJJwfGWrbh?= NVfVb5pqOjR4NU[3OFY>
CMeC-1 NVX1blVmS2WubDDWbYFjcWyrdImgRZN{[Xl? MVOyNE82OCEQvF2= NWHme|RyPDhiaB?= NVnRcG5rcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MWCyOFY2Pjd2Nh?=
LMeC Mn3WR4VtdCCYaXHibYxqfHliQYPzZZk> NVX6N3BlOjBxNUCg{txO MoLSOFghcA>? MUPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M4LhcVI1PjV4N{S2
CMeC-1 NGrwcmxHfW6ldHnvckBCe3OjeR?= NWjvd5R6OjBxNUCg{txO NXvxOHl5PDhiaB?= MmDkbY5lfWOnczDHNU1UKGG{cnXzeC=> NFvie|UzPDZ3Nke0Oi=>
LMeC NXXxdFRDTnWwY4Tpc44hSXO|YYm= MUWyNE82OCEQvF2= MVu0PEBp MX7pcoR2[2W|IFexMXMh[XK{ZYP0 MY[yOFY2Pjd2Nh?=
CMeC-1 MkfFSpVv[3Srb36gRZN{[Xl? Mmn6NlAwPTBizszN NGC1WoU1QCCq NVj5TpRt\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWjxU5ltOjR4NU[3OFY>
LMeC NX3uOIVtTnWwY4Tpc44hSXO|YYm= MXWyNE82OCEQvF2= NHrVSZU1QCCq MVfk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYiyOFY2Pjd2Nh?=
CMeC-1 NHX4SZpHfW6ldHnvckBCe3OjeR?= NVrhTFVUOjBxNUCg{txO MX:0PEBp NH;tUm9qdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MlTONlQ3PTZ5NE[=
LMeC M2X2V2Z2dmO2aX;uJGF{e2G7 NWTCXW9nOjBxNUCg{txO MkL3OFghcA>? M2fvXIlv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> MlHTNlQ3PTZ5NE[=
OVCAR-3 M4LZemNmdGxiVnnhZoltcXS7IFHzd4F6 MXGxNEDDvU1? NFjJfIwyKGh? NXHXbXdH\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? Mk\INlQ2OjB{Mke=
OVCAR-3 NX;EPYk5SXCxcITvd4l{KEG|c3H5 MYSxNEDDvU1? MWKxJIg> NVvFVotweHKxbX;0[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGyb4D0c5Nqe8Li Mm\YNlQ2OjB{Mke=
OVCAR-3 MVXGeY5kfGmxbjDBd5NigQ>? NEnmd3UyOCEEtV2= Mn3FNUBp NX\yWmt[\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZT25xsA> NGDmSZgzPDV{MEKyOy=>
OVCAR-3 NIHEb|ZHfW6ldHnvckBCe3OjeR?= M1O4flExKML3TR?= M3qwTFEhcA>? MVnkc5dvNXKnZ4XsZZRmeyCQRj5OvmIh[WO2aY\heIlwdiCrbnT1Z4VlKGK7IIDhZ4xqfGG6ZXy= MWeyOFUzODJ{Nx?=
OVCAR-3 NVK0PWhtTnWwY4Tpc44hSXO|YYm= NUDpS3F6OTBiwsXN NGDPUYwyKGh? NFqxcVBqdmirYnn0d{Bx[WOuaYThfIVtNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NFfrXWQzPDV{MEKyOy=>
CF33 MXjGeY5kfGmxbjDBd5NigQ>? NVLncZRzOTByIN88US=> M4DvTlI1KGh? NYj6W2hqcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBEV1hvMjDwdo91\WmwIHX4dJJme3Orb36= NUHOU5hGOjR3MEO3PFI>
CF33 M{jCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LBUlExNTFyMDFOwG0> MlXLNE01KGR? Ml\SbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXPIfod{OjR3MEO3PFI>
CF33 MVTGeY5kfGmxbjDBd5NigQ>? M1LSc|ExNTFyMDFOwG0> NID2coE1NTJ2IHi= MmH2[IVkemWjc3XzJINmdGy|IHnuJJRp\SCVIIDoZZNmKGGwZDDpcoNz\WG|ZYOgZ4VtdHNiaX6gS|AwTzFiYYLy[ZN1 NXXnU40{OjR3MEO3PFI>
LNCaP M2XCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGyM|UwOTBizszN NWq5d25KQTZiaB?= MU\pcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XSxco\hd5RifGmw MYWyOFI6Pjl5OB?=
LNCaP NF\oZlVCeG:ydH;zbZMhSXO|YYm= Mof3Nk82NzFyIN88US=> MmToPVYhcA>? NGDwSXdqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> MWeyOFI6Pjl5OB?=
PC-3  M1vQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK2c3pROC13MDFOwG0> NVLjfnJRPDkkgJno MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NHexT5YzPDF{N{i4Ni=>
PC-3  M{LMSWNmdGxiVnnhZoltcXS7IFHzd4F6 M3TLOVAuOTByIN88US=> MWK3NkBp NHPXdnll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NXPTcXUxOjRzMke4PFI>

... Click to View More Cell Line Experimental Data

In vivo試験 Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]
臨床試験 Celecoxib is currently in Phase II clinical trials in patients with recurrent respiratory papillomatosis.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

COX enzyme assay in vitro Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.

細胞アッセイ: [2]

細胞株 HNE1 and CNE1-LMP1
濃度 0-75 μM
反応時間 48 hours
実験の流れ The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.

動物実験: [1]

動物モデル A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
製剤 Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
投薬量 ≤200 mg/kg
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Celecoxib SDF
分子量 381.37
化学式

C17H14F3N3O2S

CAS No. 169590-42-5
保管 2年-20℃
6月-80℃in solvent
別名 SC 58635
溶解度 (25°C) * In vitro DMSO 76 mg/mL (199.28 mM)
エタノール 33 mg/mL (86.53 mM)
<1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

カスタマーフィードバック (2)


Click to enlarge
Rating
Source Br J Pharmacol, 2014, 171(2), 498-508. Celecoxib purchased from Selleck
Method Metabolic evaluation
Cell Lines Wild-type and EC-AMPK mice
Concentrations 50 mg·kg−1 ·day−1
Incubation Time 4 weeks
Results The treatment with either drughad no effects on body weight and blood glucose levels(A), but significantly decreased the circulating triglyceride and cholesterol levels in EC-AMPK mice (B).

Click to enlarge
Rating
Source J Cell Physiol, 2014, 10.1002/jcp.24843. Celecoxib purchased from Selleck
Method Live-dead assay
Cell Lines HCC38 cells
Concentrations 5.0 uM
Incubation Time 24 h
Results Initial studies examined whether there was a toxic interaction between the PDE5 inhibitor sildenafil and the non-steroidal anti-inflammatory drug celecoxib. In mammary carcinoma cell lines growing in 10% fetal calf serum sildenafil and celecoxib interacted in a greater than additive fashion to kill parental wild type tumor cells as well as anoikis resistant variants of these cells.

文献中の引用 (6)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related COX 阻害剤

  • Xanthohumol

    Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.

  • AZD3839

    AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

  • A-438079 HCl

    A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.

  • PF-03084014 (PF-3084014)

    PF-03084014 (PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Phase 2.

  • Indomethacin

    Indomethacin(Indocid, Indocin) is a non-steroidal anti-inflammatory compound commonly used to reduce fever, pain, stiffness, and swelling.

  • Lornoxicam

    Lornoxicam is a COX-1 and COX-2 inhibitor with IC50 of 5 nM and 8 nM, respectively.

  • Aspirin

    Aspirin is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.

  • Rofecoxib

    Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.

  • Ketorolac

    Ketorolacは非選択COX阻害剤、人間COX-1とCOX-2に作用する時、IC50がそれぞれ1.23 µM と3.50 µM になる。

    Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).

最近チェックしたアイテム

Tags: Celecoxibを買う | Celecoxib供給者 | Celecoxibを購入する | Celecoxib費用 | Celecoxib生産者 | オーダーCelecoxib | Celecoxib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ